Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) Stock

About Actinium Pharmaceuticals, Inc. (Delaware)

Actinium Pharmaceuticals, Inc. (Delaware) is led by CEO Sandesh C. Seth, employs 31 people, headquartered in US, publicly traded since 2012.

Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) stock trades at $1.52 with a market capitalization of $47.79M. The stock is valued at a price-to-earnings (P/E) ratio of 3.25, price-to-book of 1.21, price-to-sales of 1.05. Over the past 52 weeks the stock has ranged between $0.73 and $1.74, and currently trades 12.6% below its 52-week high.

On profitability, Actinium Pharmaceuticals, Inc. (Delaware) generates a return on equity (ROE) of 83.42%, above the typical market range of roughly 12-15%, return on capital employed of 30.93%, a net profit margin of 32.23%.

Actinium Pharmaceuticals, Inc. (Delaware) by the numbers, 2016–2025

Between 2016 and 2025 Actinium Pharmaceuticals, Inc. (Delaware) reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-34.0M.

The most recent net margin is 32.23%. On a trailing twelve-month basis to Jun '26, revenue is $35.0M and net profit $11.0M.

Borrowings stand at $2.0M, cash from operations was $-25.0M in the latest year, positive in 1 of the last 10.

Return on equity has averaged -152.0% over five years, and was -425.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) — frequently asked questions